Else Nutrition Achieves Gross Profit, FDA Signals Clearer Path for Plant-Based Infant Formula
BABYF is trading near its 52-week low of $0.038 (13% above the low).
Summary
Else Nutrition Holdings Inc. reported fiscal year 2025 financial results, highlighting a significant operational turnaround. The company achieved a return to positive gross profit of $320,000, reversing a $1.2 million gross loss in 2024, primarily due to substantial cost reductions, including a 51% decrease in operating expenses. While U.S. revenue declined by 18.5%, management expressed confidence in achieving overall profitability within the next 12 months. Critically, the company announced major regulatory progress for its plant-based infant formula, with the FDA signaling intent to finalize updated Protein Efficiency Ratio (PER) guidance. This development is highly significant as PER requirements were previously a key blocker for their clinical studies, potentially accelerating their path to U.S. market entry. Traders will be watching for continued revenue recovery, further details on FDA guidance, and progress in their clinical development.
At the time of this announcement, BABYF was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.04 to $0.80. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.